Article
Comparison of in-vitro maturation cycles with and without in-vivo matured oocytes retrieved

https://doi.org/10.1016/S1472-6483(10)60294-5Get rights and content

Abstract

This study compared the embryological characteristics and clinical outcome of in-vitro maturation (IVM) treatment cycles with and without in-vivo matured oocytes collected following human chorionic gonadotrophin (HCG) priming. The patients were administered 10,000 IU of HCG subcutaneously when endometrial thickness reached ≤6 mm and oocyte collection was performed 35–36 h after HCG administration. The clinical outcome and embryological aspects were analysed between IVM cycles with (group 1) and without (group 2) in-vivo matured oocytes. In group 1, three (range 1–12) in-vivo matured oocytes per patient were retrieved on average. The number of good quality embryos derived from in-vivo matured oocytes in group 1 was significantly higher than those derived from in-vitro matured oocytes in group 1 and group 2 (P < 0.05). However, there was no difference between the number of good quality embryos produced from in-vitro matured oocytes in the two groups. There were 12 clinical pregnancies (40.0%) in group 1, and seven pregnancies (23.3%) in group 2. These results suggest that IVM cycles with in-vivo matured oocytes resulted in a good clinical pregnancy rate, which could be explained by the superior quality of embryos derived from the in-vivo matured oocytes.

Section snippets

Dr Son is lead clinical embryologist in the Department of Obstetrics and Gynecology at McGill Reproductive Center in Montreal. He obtained his PhD degree from Sogang University, Seoul, Korea, in 2000 and has more than 10 years of experience of clinical embryology. He started his work as a clinical embryologist at the CHA Fertility Center in 1992, and then in 2000 became IVF Laboratory Director of Maria Infertility Hospital, both located in Seoul. In 2003, Dr Son joined the McGill Reproductive

References (17)

There are more references available in the full text version of this article.

Cited by (85)

  • Alteration of final maturation and laboratory techniques in low responders

    2022, Fertility and Sterility
    Citation Excerpt :

    Follicles as small as 4 mm in diameter have been shown to contain mature oocytes, and mature oocytes from follicles with a diameter ≤10 mm after human chorionic gonadotropin (hCG) priming were associated with fertility outcomes similar to those of oocytes retrieved from larger follicles (7). However, a positive correlation between the size of the dominant follicle and the number of in vivo-matured oocytes retrieved has been reported (8, 9). Wirleitner et al. (10) evaluated oocyte maturity and blastocyst development in 1,493 individually aspirated follicles based on follicular diameter and volume (8–12 mm/0.3–0.9 mL [small], 13–23 mm/1–6 mL [medium], and ≥24 mm/>6 mL [large]).

  • Follicular fluid and supernatant from cultured cumulus-granulosa cells improve in vitro maturation in patients with polycystic ovarian syndrome

    2018, Fertility and Sterility
    Citation Excerpt :

    Previous studies have shown that, upon IVM, nearly 50% of immature oocytes reach maturation after 24–28 hours (28). Heterogeneous embryological outcomes have been reported concerning maturation (33%–82%), fertilization (19%–80%), and cleavage rate (7%–96%) after IVM (29–35). In the case of PCOS, IVM is a mild adjunct approach to IVF to achieve in vitro oocyte maturation and enhance oocyte competency for embryonic development until implantation.

  • Comparing the effects of different in vitro maturation media on IVM outcomes of MI oocytes

    2017, Middle East Fertility Society Journal
    Citation Excerpt :

    Recently, several investigations have focused on culture media optimization in order to improve the IVM techniques, but they have not been clearly analyzed yet [7–9]. In different clinical or research studies, different types of media for IVM have been applied such as human tubal fluid [10], culture medium 199 [11,12], and blastocyst medium [12] besides the commercially available MediCult IVM media (Origio A/S, Jyllinge, Denmark) and Sage IVM media (Cooper Surgical, Trumbull, Connecticut) that are often used with reasonable implantation and pregnancy rates [13]. However, applying these especial formulated commercial media have several disadvantages, such as limited shelf life and more cost than standard culture media for assisted in vitro fertilization (IVF) centers, where IVM services are not routinely performed.

  • Beneficial effects of glutathione supplementation during vitrification of mouse oocytes at the germinal vesicle stage on their preimplantation development following maturation and fertilization in vitro

    2017, Cryobiology
    Citation Excerpt :

    However, human embryo cryopreservation has some drawbacks as it requires the availability of male partners [37] and it is prohibited due to ethical, legal or religious implications in some countries and for some patients [8,13]. Cryopreservation of unfertilized oocytes is an alternative, giving flexibility in the time of IVF and potential to establish banking of oocyte donation [9,32,33,43]. Cryopreservation of oocytes at the germinal vesicle stage (GV) is a method with many clinical advantages over those at the metaphase II (MII); for example, decreasing the risk of ovarian hyperstimulation syndrome (OHSS) and the cost and duration of hormonal treatment [19,25].

View all citing articles on Scopus

Dr Son is lead clinical embryologist in the Department of Obstetrics and Gynecology at McGill Reproductive Center in Montreal. He obtained his PhD degree from Sogang University, Seoul, Korea, in 2000 and has more than 10 years of experience of clinical embryology. He started his work as a clinical embryologist at the CHA Fertility Center in 1992, and then in 2000 became IVF Laboratory Director of Maria Infertility Hospital, both located in Seoul. In 2003, Dr Son joined the McGill Reproductive Center in his present position. His research interests include in-vitro oocyte maturation, blastocyst culture and vitrification of oocyte and embryo.

Declaration: The authors report no financial or commercial conflicts of interest.

Presented at the Annual Meeting of the American Society for Reproductive Medicine, New Orleans, Louisiana, USA, October 21–25, 2006.

View full text